Chinese pharma powerhouse Hansoh joins fledgling biotechs in the Hong Kong IPO line
More than four months after first opening its doors to a big crowd of R&D focused biotechs, the Hong Kong Stock Exchange has seen a special guest walk in: A storied company running a profitable innovative and generic drug business in China.
Jiangsu Hansoh is filing for an IPO two years after rumors of a $3 billion public debut first surfaced. It was founded and still run by Huijuan Zhong, one half of a power couple towering over China’s pharma industry. Her husband, Piaoyang Sun, is the head of Jiangsu Hengrui Medicine, internationally known for a PD-1 drug Incyte paid millions to partner with.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.